



August 18, 2009

Dear Nuclear Medicine Professional:

We are pleased to report the High-Flux Reactor (HFR) in Petten, The Netherlands, has completed its scheduled maintenance and is now back on-line as planned. We expect to begin receiving molybdenum 99 (Mo 99) from HFR this weekend, as scheduled, for technetium 99m (Tc 99m) generator production next week.

This return to service increases the availability of Mo 99, but the further extension of the National Research Universal (NRU) reactor shutdown in Canada remains a concern. Supply estimates from the four major medical isotope reactors in Europe and South Africa were used to produce calendars detailing expected technetium 99m (Tc 99m) generator production and unit dose Tc 99m supply from Covidien for the U.S., Canada and Latin America through October. NOTE: Daily projections are based on current information and are subject to change.

| AUGUST | | | | | | | SEPTEMBER | | | | | | | OCTOBER | | | | | | |
|--------|----|----|----|----|----|----|-----------|----|----|----|----|----|----|---------|----|----|----|----|----|----|
| S | M | T | W | T | F | S | S | M | T | W | T | F | S | S | M | T | W | T | F | S |
| | | | | | | 1 | | | 1 | 2 | 3 | 4 | 5 | | | | | 1 | 2 | 3 |
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 | 27 | 28 | 29 | 30 | | | | 25 | 26 | 27 | 28 | 29 | 30 | 31 |
| 30 | 31 | | | | | | | | | | | | | | | | | | | |

| | | |
|--|--|---|
| Generator standing orders met with some extra; minimal Tc99m unit dose (UD) impact | Majority generator standing orders met but no extra; some Tc99m UD reduced | Shortage to generator standing orders; significant Tc99m shortage and UD impact |
|--|--|---|

NOTE: Calendars reflect same projections shown in August 5 letter.

This worldwide shortage affects the entire chain—reactors and Mo 99 processors, Tc 99m generator manufacturers, radiopharmacies, clinicians and, most importantly, the patients. Though it comes at a cost, each of us is doing our part to maximize the availability of this crucial isotope to minimize patient impact. We are confident our industry will continue to do what is needed to help ensure the broadest patient access to potentially life-saving nuclear medicine procedures.

Regardless of generator supply levels, Covidien endeavors to fairly and thoughtfully distribute our available isotope supply to reach as many patients as practicable globally. To learn more about the current Mo 99 supply situation, please visit the special update page on our web site at www.covidien.com/Mo99supply.

Sincerely,

John Collins, MBA, CNMT, RT (R)(N)
Vice President, U.S. Commercial Operations